Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

<p>Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Johanna K Ecke (Autor), Luis Del Valle (Autor), Amanda Parker Struckhoff (Autor), Piotr Waligorski (Autor), Krzysztof Reiss (Autor), Francesca Peruzzi (Autor)
Format: Knjiga
Izdano: International Journal of Veterinary Science and Research - Peertechz Publications, 2015-10-16.
Teme:
Online pristup:Connect to this object online.
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_ijvsr_000003
042 |a dc 
100 1 0 |a Johanna K Ecke  |e author 
700 1 0 |a  Luis Del Valle  |e author 
700 1 0 |a  Amanda Parker Struckhoff  |e author 
700 1 0 |a  Piotr Waligorski  |e author 
700 1 0 |a  Krzysztof Reiss  |e author 
700 1 0 |a Francesca Peruzzi  |e author 
245 0 0 |a Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate 
260 |b International Journal of Veterinary Science and Research - Peertechz Publications,   |c 2015-10-16. 
520 |a <p>Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high cholesterol and high triglyceride levels in humans. However, fenofibrate has also been shown to possess anti-proliferative and anti-metastatic properties against several aggressive and highly metastatic tumors in vitro and in small animal models.We report a case of a 6.5-year-old dog diagnosed with a splenic hemangiosarcoma and treated solely with micronized fenofibrate, administered orally once a day following splenectomy. The dog survived for over 26 months (804 days) after initial diagnosis without signs of adverse effects due to fenofibrate treatment</p> 
540 |a Copyright © Johanna K Ecke et al. 
546 |a en 
655 7 |a Case Report  |2 local 
856 4 1 |u https://doi.org/10.17352/ijvsr.000003  |z Connect to this object online.